Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goserelin extended-release microspheres vs sustained-release implant in prostate cancer (real-world)
ChiCTR2500100634Phase 4Not yet recruiting
- Sponsor
- Aerospace Center Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of goserelin in prostate cancer (PCa) (2 arms), sponsored by Aerospace Center Hospital. Primary endpoint: Percentage of patients with serum testosterone ≤20 ng/dL on day 29 after first administration. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500100634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100634.